Frost & Sullivan says, 'The MicroCam platform possesses the potential not only to redefine the economics of endoscopy in North America, but also to expand access to minimally invasive surgery for billions of patients globally.'
SAN RAFAEL, Calif., Dec. 1, 2014 /PRNewswire/ — Sanovas Inc., a Life Science company accelerating the development and commercialization of next-generation, micro-invasive diagnostics, devices and drug delivery technologies, announced today that it has been awarded the 2014 Global Frost & Sullivan Award for "New Product Innovation Leadership in Endoscopic Imaging" for its MicroCam™ Technology Platform. The award will be presented to Sanovas CEO Larry Gerrans at a Frost & Sullivan ceremony on Dec. 2, 2014, in Toronto, Canada.
Photo – http://photos.prnewswire.com/prnh/20141126/161115
The MicroCam System represents an entirely new concept in medical imaging that has not been possible until now. The MicroCam System is a highly integrated platform of proprietary micro optics, electronics and software. The plug-and-play capabilities of the 3mm-diameter, 5mm-long MicroCam System enable it to be sold as an OEM product as well as a branded MicroCam product, which MicroCam Inc., a Sanovas subsidiary company, is pursuing simultaneously with its OEM strategy.
"Sanovas is commercializing a groundbreaking endoscopic platform that can provide the functionality of a high-end flexible endoscope without the entanglement or costs of expensive capital equipment," said Frost & Sullivan Research Analyst Venkat Rajan. "The MicroCam platform possesses the potential not only to redefine the economics of endoscopy in North America, but also to expand access to minimally invasive surgery for billions of patients globally."
Rajan noted that MicroCam obviates the need for a cart-based console and its associated components. A truly plug-and-play solution, the innovative MicroCam's construct allows for it to be easily connected to a user's computing device—whether it be a laptop, tablet, PC, smart phone or other display.
"The unique competitive advantage and humanitarian opportunity for MicroCam is that its profile and cost is going to disrupt the economics of endoscopy in the existing markets, largely comprised of approximately 750 million addressable patients, while commensurately expanding access to minimally invasive surgery for nearly 3.1 billion patients in the emerging markets," said Larry Gerrans, co-founder, president and CEO of Sanovas, Inc. and inventor of the MicroCam system. "Moreover, incorporating MicroCam into existing instrumentation is going to forever change the paradigm of endoscopy. The status quo has been to use multiple tools to triangulate on a single image that is directed at the operative site. Integrating MicroCam into instrumentation will create a new environment that uses multiple tools that each possesses onboard imaging to triangulate on the target anatomy and provide the clinician multiple angles of view. This is a much safer and efficacious means to improving the precision of minimally invasive surgery."
Gerrans, who has launched over 10 successive generations of surgical cameras in his career, pointed out that the MicroCam platform eliminates nearly 90% of the components required to generate an endoscopic image and reduces the cost factors for providers to acquire an endoscopic imaging system by as much as 80%.
"There is no question that the MicroCam platform is highly disruptive to the handful of legacy endoscopy companies who have long competed in this marketplace. However, this is a technology whose time has come. Our profession mandates that we serve the greater good, and that responsibility requires our innovations to meet the needs of the emerging global marketplace," said Gerrans.
About Sanovas
At the heart of the Sanovas companies' scientific advances is the miniaturization of tools for minimally invasive surgery, or "M-I-S." Its products extend access beyond current limits, enabling physicians to diagnose and perform therapeutic interventions in spaces as small as 1 millimeter in diameter that have previously been unreachable. Sanovas expects to commercialize the technology in coordination with its various partners to address unmet clinical needs in Oncology, Pulmonology, Cardiology, Neurosurgery, ENT, GI, General Surgery, Urology and Gynecology.
Contacts:
Steve Goldsmith, Sanovas, 415-729-9391 x1023, sgoldsmith@sanovas.com
Ron Trahan, Ronald Trahan Associates, 508-359-4005 rtrahan@ronaldtrahan.com